Before revision:  COVID-19 , the disease caused by the coronavirus SARS-CoV-2, has inflicted considerable suffering on the human population. In this paper, we aim to significantly expand the resources available to biological and clinical researchers who are developing therapeutic targets for drug development and repositioning. Taking a genome-scale, systems-level view of virus-host interactions, we adapt and specialize network label propagation methods to prioritize drug targets based on their probability to inhibit host-pathogen interactions or their downstream signaling targets.
After revision:  COVID-19 , we present a genome-scale, systems-level view of virus-host interactions, we adapt and specialize network label propagation methods to prioritize drug targets based on their probability to inhibit host-pathogen interactions or their downstream signaling targets.